Anticoagulant fusion protein anchored to cell membrane

a fusion protein and anticoagulant technology, applied in the field of inhibition of blood coagulation, can solve the problems of lysis and death of ecs of transplants, the inability to match ever-rising demands for xenografts, and the inability to supply suitable transplant organs, so as to increase the effect of inhibiting the coagulation cascad
US20050118160A1Inactive Publication Date: 2005-06-02IMPERIAL INNOVATIONS LTD
4 Cites 7 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
IMPERIAL INNOVATIONS LTD
Publication Date
2005-06-02
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF THE INVENTION

[0001] This invention relates to the inhibition of blood coagulation, especially during organ rejection. BACKGROUND TO THE INVENTION

[0002] The surgical technique of organ transplantation has now been successfully practised for several decades and, because of its success, the procedure has become widespread and, arguably, routine. However, the supply of suitable transplant organs is not able to match ever-rising demands. Because of the shortage of suitable human (ie. allogeneic) organs, the possibility of using animal (ie. xenogeneic) organs in human transplant operations (“xenografting” or “xenotransplantation”) has been receiving increased attention in recent years (eg. Nature 1997; 385: 285). Porcine donor organs are thought to be suitable candidates because pigs are anatomically and physiologically similar to humans and are in abundant supply.

[0003] Xenografting is currently hindered, however, by the severe and well-documented problems of rejection. This ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More